MIST
Milestone Pharmaceuticals Inc.·Healthcare
1.40
0.000%(+0.00)
Close PriceLast Updated: — ET
52W L: $1.0052W H: $3.06
MIST NEWS
globenewswire.com
May 14
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ to take place on Tuesday, May 19, 2026 in New York.
fool.com
May 13
Why Milestone Pharmaceuticals Stock Wilted on Wednesday
The biotech fell well short of analyst projections in the first quarter.
marketbeat.com
May 13
Milestone Pharmaceuticals Q1 Earnings Call Highlights
Milestone Pharmaceuticals NASDAQ: MIST said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular tachycardia, or PSVT, while the company also moved ahead with a Phase 3 program in atrial fibrillation with rapid ventricular rate.
seekingalpha.com
May 13
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript
benzinga.com
May 13
Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) reported first-quarter earnings on Wednesday before the market opened. Here's a rundown of the report.
zacks.com
May 13
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of $0.06. This compares to a loss of $0.31 per share a year ago.
